[go: up one dir, main page]

GR1007755B - A new asymmetric method for the synthesis of rivastigmine hydrogen tartrate, crystal form type ii, its implementation for preparing oral solution for the treatment of dementia and dependences - Google Patents

A new asymmetric method for the synthesis of rivastigmine hydrogen tartrate, crystal form type ii, its implementation for preparing oral solution for the treatment of dementia and dependences

Info

Publication number
GR1007755B
GR1007755B GR20120100007A GR20120100007A GR1007755B GR 1007755 B GR1007755 B GR 1007755B GR 20120100007 A GR20120100007 A GR 20120100007A GR 20120100007 A GR20120100007 A GR 20120100007A GR 1007755 B GR1007755 B GR 1007755B
Authority
GR
Greece
Prior art keywords
treatment
oral solution
crystal form
hydrogen tartrate
dementia
Prior art date
Application number
GR20120100007A
Other languages
Greek (el)
Other versions
GR20120100007A (en
Inventor
Γεωργιος Σπυριδωνος Φαμπιος
Original Assignee
Farmellas Enterprises Limited,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmellas Enterprises Limited, filed Critical Farmellas Enterprises Limited,
Priority to GR20120100007A priority Critical patent/GR1007755B/en
Publication of GR20120100007A publication Critical patent/GR20120100007A/en
Publication of GR1007755B publication Critical patent/GR1007755B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/001—Amines; Imines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention brought a new, rapid and convenient method for industrial synthesis of (S)-3-[1 -(dimethylamino)ethyl]phenyl-N-ethyl-N-methyl-carbamate hydrogen-(2R, 3R)-tartrate (Rivastigmine Hydrogen Tartrate), crystal form Type II, as well as its use for the manufacture of an oral solution with water clusters, stabilized in 4D mM citrate buffer for the treatment of dementia associated with Alzheimer's and Parkinson's disease and for severe addictions from smoking and drugs. In the present invention presented a stabilized pharmaceutical composition of the oral solution of rivastigmine hydrogen tartrate, stabilized in citric acid / sodium citrate buffer of 40mM capacity with water clusters useful for the treatment of dementia associated with Alzheimer's and Parkinson's disease and for severe addictions from smoking and drugs.
GR20120100007A 2010-12-09 2010-12-09 A new asymmetric method for the synthesis of rivastigmine hydrogen tartrate, crystal form type ii, its implementation for preparing oral solution for the treatment of dementia and dependences GR1007755B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20120100007A GR1007755B (en) 2010-12-09 2010-12-09 A new asymmetric method for the synthesis of rivastigmine hydrogen tartrate, crystal form type ii, its implementation for preparing oral solution for the treatment of dementia and dependences

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20120100007A GR1007755B (en) 2010-12-09 2010-12-09 A new asymmetric method for the synthesis of rivastigmine hydrogen tartrate, crystal form type ii, its implementation for preparing oral solution for the treatment of dementia and dependences

Publications (2)

Publication Number Publication Date
GR20120100007A GR20120100007A (en) 2012-07-13
GR1007755B true GR1007755B (en) 2012-11-08

Family

ID=46467342

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20120100007A GR1007755B (en) 2010-12-09 2010-12-09 A new asymmetric method for the synthesis of rivastigmine hydrogen tartrate, crystal form type ii, its implementation for preparing oral solution for the treatment of dementia and dependences

Country Status (1)

Country Link
GR (1) GR1007755B (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7172885B2 (en) * 2004-12-10 2007-02-06 Cambrex North Brunswick, Inc. Thermostable omega-transaminases
HUE038434T2 (en) * 2010-06-17 2018-10-29 Codexis Inc Biocatalysts and methods for the synthesis of (s)-3-(1-aminoethyl)-phenol

Also Published As

Publication number Publication date
GR20120100007A (en) 2012-07-13

Similar Documents

Publication Publication Date Title
MX343620B (en) Polymorphic form of pridopidine hydrochloride.
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
MY149731A (en) Compounds
MX2010013766A (en) Rasagiline for parkinson's disease modification.
IL196627A0 (en) Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-
PH12012500693A1 (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
MX359229B (en) Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative.
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
MX344238B (en) Tetrazole compounds and methods of making and using same.
MX2012007759A (en) Intermediate compounds and processes for the preparation of tapentadol and related compounds.
WO2010139979A3 (en) Processes for preparing crystalline forms of dasatinib
MY156285A (en) Co-crystals of tramadol and coxibs
WO2009120919A3 (en) Fenofibrate dosage forms
MX2009006345A (en) Compounds useful as protein kinase inhibitors.
MX2012005356A (en) Pharmaceutical substances on the basis of mitochondrially addressed antioxidants.
WO2011009039A3 (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
NZ599757A (en) The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders
MA34055B1 (en) AGOMELATIN HYDRATE HYDROCHLORIDE AND ITS PREPARATION
UA86441C2 (en) (2-hydroxyethyl)trimethylammonium thiooctate (choline thioctate), having hepatoprotective, hypoamoniemic and detoxic action, method for production thereof and pharmaceutical compositions based on it
WO2011089126A3 (en) Novel retigabine composition
MX2013008340A (en) Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer.
WO2012024100A3 (en) Process for preparing aminocyclohexyl ether compounds
UA106907C2 (en) Stabilized pharmaceutical composition

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20130122